Leland S. Hu1,2, Leslie C. Baxter3,
Dilini S. Pinnaduwage4, Todd Jensen5, Amylou C. Dueck6,
Jennifer M. Eschbacher7, Joseph E. Heiserman2, John P.
Karis2, Josef Debbins3, Jonathan Placencia Placencia8,
Seban Liu3, Burt G. Feuerstein9, Kathleen M. Schmainda10
1Radiology, Mayo Clinic, Arizona,
Scottsdale, AZ, United States; 2Radiology, Neuroradiology Section,
St. Joseph's Hospital - Barrow Neurological Institute, Phoenix, AZ, United
States; 3Keller Center for Imaging Innovation, St. Joseph's
Hospital - Barrow Neurological Institute, Phoenix, AZ, United States; 4Radiation
Oncology, University of California - San Francisco, San Francisco, CA, United
States; 5Imaging Biometrics, LLC; 6Biostatistics, Mayo
Clinic, Arizona, Scottsdale, AZ, United States; 7Neuropathology,
St. Joseph's Hospital - Barrow Neurological Institute, Phoenix, AZ, United
States; 8Biomedical Engineering, Arizona State University, Tempe,
AZ, United States; 9Neuro-Oncology, St. Joseph's Hospital - Barrow
Neurological Institute, Phoenix, AZ, United States; 10Radiology,
Medical College of Wisconsin, Milwaukee, WI, United States
We
validate mathematical modeling correction of relative cerebral blood volume
(rCBV) in regards to effectiveness of 1) minimizing T1W leakage and 2)
correcting T2/T2*W residual effects, by correlating localized measures with
image-guided tissue histopathology and microvascular density from
stereotactic biopsies in post-treatment high-grade gliomas.